Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review.
Simple Summary: irAEs can happen in any patient receiving ICIs, either in a metastatic or non-metastatic setting. Given their increasing application in clinical practice, understanding the underlying causes and manifestations, as well as diagnosis and management, is of great importance, making it on...
| Publicado en: | Current Oncology Vol. 31; no. 1; pp. 28 - 44 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jan2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191175346&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 191175346 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Jan2026 vid: 31 iid: 1 pid: 97109 pub: MDPI artinfo: ui: 191175346 10.3390/curroncol33010028 191175346 ppf: 28 ppct: 16 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review. aug: au: Ardakani, Khashayar Yazdanpanah Passarella, Gaia Lania, Andrea Gerardo Antonio Clementi, Thoma Dario Fanti, Alessandro Pepe, Francesca Fulvia Capici, Serena Cazzaniga, Marina Elena affil: School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy sug: ab: Simple Summary: irAEs can happen in any patient receiving ICIs, either in a metastatic or non-metastatic setting. Given their increasing application in clinical practice, understanding the underlying causes and manifestations, as well as diagnosis and management, is of great importance, making it one of the most important topics to be investigated regarding the effect on a patient's life quality as well as quality of treatment. Here, we discuss the cases of two patients with the diagnosis of TNBC, receiving an anti-PD1 mAb, pembrolizumab, in the neoadjuvant setting presenting with dual endocrine-related irAEs. The flow of diagnosis, treatment, and patient's consideration as well as risk factors are explained and discussed by the authors, while the management of endocrine-related adverse events is explained by two endocrinologists with expertise in management of these complications. Pembrolizumab, an anti-PD-1 monoclonal antibody, showed promising results in the treatment of different types of solid tumors and generally an improvement in overall survival and patients' outcome. However, as a drug that targets the immune system to enhance the anti-tumor response, it simultaneously increases the risk of autoimmune reactions, producing immune-related adverse events (irAEs). These irAEs might involve any body organ, and in some cases may lead to treatment discontinuation. In this article, we discuss two cases of triple-negative breast cancer (TNBC) patients, who developed irAEs during the course of neoadjuvant pembrolizumab, highlighting the mechanism of the reactions, possible clinical manifestations, and potential management. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|